During the past decade, CHP-HGSA, Unidade Clinica de Paramiloidose conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "CHP-HGSA, Unidade Clinica de Paramiloidose" are "Amyloidosis" (2 trials), "FAP" (2 trials), "Familial Amyloid Polyneuropathy" (2 trials), "TTR" (2 trials) and "Transthyretin" (2 trials). Many other conditions were trialed in "CHP-HGSA, Unidade Clinica de Paramiloidose" in a lesser frequency.

Most popular intervention types in "CHP-HGSA, Unidade Clinica de Paramiloidose" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Inotersen" (2 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHP-HGSA, Unidade Clinica de Paramiloidose" are 2 trials for "All" genders.

Currently, there are NaN active trials in "CHP-HGSA, Unidade Clinica de Paramiloidose". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in CHP-HGSA, Unidade Clinica de Paramiloidose, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHP-HGSA, Unidade Clinica de Paramiloidose, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".